RESEARCH TRIANGLE PARK, N.C.,
Feb. 14, 2011 /PRNewswire/ --
Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) announced
today that its shareholders voted to approve the company's proposed
merger with Grifols S.A. at a special meeting of shareholders. The
preliminary tabulation indicates that approximately 86 percent of
the outstanding shares were voted in favor of the
transaction. Closing of the transaction remains subject to
resolution of the review by the Federal Trade Commission (FTC). As
the acquirer, Grifols agreed to provide written notice to the FTC
staff at least thirty days prior to closing the Talecris-Grifols
merger and, in any event, not to close the Talecris-Grifols
merger until after 11:59 p.m. on
March 20, 2011. There can be no
assurance that Grifols will reach resolution with the FTC by
March 20, 2011.
About Talecris Biotherapeutics: Inspiration. Dedication.
Innovation.
Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces
critical care treatments for people with life-threatening disorders
in a variety of therapeutic areas including immunology,
pulmonology, neurology and hemostasis. For more information, please
visit: www.talecris.com
SOURCE Talecris Biotherapeutics, Inc.